CGRP ANTAGONISTS FOR TREATING MIGRAINE BREAKTHROUGH
Disclosed are methods of treating breakthrough migraine in patients using breakthrough CGRP antagonists. Also disclosed are methods for the prophylactic treatment of migraine.
1 . A method for treating, preventing, alleviating or reducing the frequency of occurrence of headache in a patient in need thereof, comprising administering to the patient rimegepant, wherein said patient is concurrently undergoing treatment with a clostridial derivative.
2 . The method according to claim 1 , wherein the rimegepant is in the form of a hemisulfate sesquihydrate salt.
3 . The method according to claim 1 , wherein the clostridial derivative is botulinum toxin.
4 . The method according to claim 1 , wherein the headache is a migraine headache, a cluster headache, or a combination thereof.
5 . A method for treating, preventing, alleviating or reducing the frequency of occurrence of migraine or a symptom of migraine in a patient in need thereof, comprising administering to the patient rimegepant, wherein said patient is concurrently undergoing treatment with a clostridial derivative.
6 . The method according to claim 5 , wherein the rimegepant is in the form of a hemisulfate sesquihydrate salt.
7 . The method according to claim 5 , wherein the clostridial derivative is botulinum toxin.
8 . The method according to claim 5 , wherein the patient experiences reduced severity of migraine after treatment with the rimegepant.
9 . The method according to claim 5 , wherein the migraine is breakthrough migraine.
10 . A method for treating, preventing, alleviating or reducing the frequency of occurrence of headache in a patient in need thereof, comprising administering to the patient zavegepant, wherein said patient is concurrently undergoing treatment with a clostridial derivative.
11 . The method according to claim 10 , wherein the zavegepant is administered intranasally.
12 . The method according to claim 10 , wherein the clostridial derivative is botulinum toxin.
13 . The method according to claim 10 , wherein the patient experiences reduced severity of headache after treatment with the zavegepant.
14 . The method according to claim 10 , wherein the headache is a migraine headache, a cluster headache, or a combination thereof.
15 . A method for treating, preventing, alleviating or reducing the frequency of occurrence of migraine or a symptom of migraine in a patient in need thereof, comprising administering to the patient zavegepant, wherein said patient is concurrently undergoing treatment with a clostridial derivative.
16 . The method according to claim 15 , wherein the zavegepant is administered intranasally.
17 . The method according to claim 15 , wherein the clostridial derivative is botulinum toxin.
18 . The method according to claim 15 , wherein the patient experiences reduced severity of migraine after treatment with the zavegepant.
19 . The method according to claim 15 , wherein the symptom of migraine is reduced after treatment with the CGRP antagonist.
20 . The method according to claim 15 , wherein the migraine is breakthrough migraine.